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Abstract
This study investigated the genotoxicity of Lapachol (LAP) evaluated by wing spot test of Drosophila melanogaster in
the descendants from standard (ST) and high bioactivation (HB) crosses. This assay detects the loss of hetero-
zygosity of marker genes expressed phenotypically on the fly’s wings. Drosophila has extensive genetic homology to
mammals, which makes it a suitable model organism for genotoxic investigations. Three-day-old larvae from ST
crosses(femalesflr
3/TM3,Bd
sxmalesmwh/mwh),withbasallevelsofthecytochromeP450andlarvaeofhighmeta-
bolic bioactivity capacity (HB cross) (females ORR; flr
3/TM3, Bd
s x males mwh/mwh), were used. The results showed
that LAP is a promutagen, exhibiting genotoxic activity in larvae from the HB cross. In other words, an increase in the
frequency of spots is exclusive of individuals with a high level of the cytochrome P450. The results also indicate that
recombinogenicity is the main genotoxic event induced by LAP.
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Approximately two-thirds of the biological diversity
worldwide occurs in tropical zones, mainly in developing
countries,especiallyinBrazilwithseveraldifferentbiomes
(Vieira, 1999). The Cerrado, the second largest ecological
domain, covers approximately 25% of the total surface
area, with a continuous herbaceous stratum joined to an ar-
boreal one, with variable density of woody species, and
Around 220 of those species reportedly used in traditional
medicine (Vieira and Martins, 1998).
Lapachol (LAP), 4-hydroxy-3-(3-methylbut-2-
enyl)naphthalene-1,2-dione, is a naphthoquinone found in
manyvegetablespeciesoftheBignoniaceaefamily,specif-
ically those of the genus Tabebuia (Tabebuia aurea,
Tabebuia impetiginosa, Tabebuia ochracea) from the
Cerrado. It is endowed with antimicrobial qualities active
in combating bacterial, fungal and virus infections, as well
as, and more importantly, cancer (Fonseca et al., 2004;
Castellanos et al., 2009). This quinone showed significant
in vivo anti-tumor activity in several early mouse models
(Raoetal.,1968),sincethenprogressingtoclinicaltrialsby
the National Cancer Institute (NCI) in the 1970’s. How-
ever, in 1974, the NCI concluded that the high concentra-
tions required for efficient chemotherapy in human cancer
treatment, unfortunately also gave rise to extremely toxic
side-effects, thereby justifying its rejection (Suffness and
Douros, 1980; Castellanos et al., 2009). Notwithstanding,
recent results have shown that lapachol, isolapachol and its
acetylderivative are significantly active against
Biomphalaria glabrata, the intermediate host of
Schistosoma mansoni (Santos et al., 2000; Lima et al.,
2002). According to Lima et al. (2004), antileishmanial ac-
tivity was found to be efficient against certain viral strains
including herpes virus Types I and II (Silva et al., 2002).
LAPprovedtobeavitaminK-antagonistantigen,thuspos-
sibly targeting vitamin K-dependent reactions (Dinnen and
Ebisuzaki, 1997), besides also being bio-activated by P450
reductase to reactive species which promote DNA scission,
through redox cycling with generation of free radicals (Ku-
magai et al., 1997). The enzyme responsible for bioacti-
vating lapachol, thereby leading to the generation of ROS
capableofcausingDNAdamage,wasunknown.Animmu-
noinhibition study with antibodies against cytochrome
P450 reductase (P450R), revealed that P450R was a pre-
dominant enzyme in catalyzing the one-electron reduction
of lapachol (Kumagai et al., 1997).
Genetics and Molecular Biology, 33, 3, 558-563 (2010)
Copyright © 2010, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to Júlio César Nepomuceno. Instituto de
Genética e Bioquímica, Universidade Federal de Uberlândia, Av.
Para 1720, 38400-902 Uberlândia, MG, Brazil. E-mail:
nepomuceno@ufu.br.
Short CommunicationGeneration of reactive oxygen species, superoxide
anion radical and hydroxyl radical during the metabolism
of LAP by P450 reductase, was confirmed by acetylated
cytochrome reduction assay in the absence and presence of
Cu, Zn-SOD (Superoxide Dismutase), and electron spin
resonance (ESR) studies (Kumagai et al., 1997).
Certain synthetic derivatives of lapachol, such as mo-
no-(arylimines)-o quinones derived from ß-lapachone, also
inhibit the activity of the enzyme topoisomerases (Este-
ves-Souza et al., 2007). DNA supercoiling is a precisely
regulated process that influences DNA replication, tran-
scription and packaging. The DNA topoisomerases are en-
zymes that modulate the topological state of DNA.
The wing somatic mutation and recombination test
(SMART), when using Drosophila melanogaster, is capa-
ble of detecting a vast range of genetic abnormalities, such
as mutations, deletions and somatic recombinations (Graf
et al., 1984; Würgler et al., 1984). During the embryonic
developmentofD.melanogaster,imaginaldisc-cellgroups
proliferate mitotically during larvae growth, until reaching
the point of differentiating during metamorphosis of body
structures of the adult insect. If genetic alteration occurs in
any one of the imaginal disc cells, these changes will be
present in all the following cells, subsequently forming a
mutant cell clone. This being the case, mutant cells will be
detected as a spot of mutant trichome on adult insects’
wings (Guzmán-Rincón and Graf, 1995).
The drug doxorubicin (DXR) is capable of creating a
varietyoffreeradicalsincells,thiscapabilitybeingconsid-
ered critical in its anti-tumoral effect (Keizer et al., 1990).
The production of free radicals acts directly on the nucleus,
therebygeneratingunfavorableconditionsforcelldivision.
This cytotoxic mechanism appears to be the principal anti-
tumoraleffectofDXR(Keizeretal.,1990).Doxorubicinis
also the genotoxic agent that inhibits topoisomerase II ac-
tivity, with the consequential accumulation of DNA strand
breaks which, if not repaired by the cell, can provoke muta-
tions and chromosomal aberrations (Islaih et al., 2005). In
D. melanogaster, DXR, analyzed through SMART testing,
was classified as a strong mutagen capable of inducing all
types of spots (Frei et al., 1985).
Hence, the objective of the present study was to eval-
uate the genotoxic effects of LAP by applying the
Drosophila melanogaster wing spot test. The influence of
differences in the level of cytochrome P450 on LAP geno-
toxic activity were evaluated by way of standard (ST) and
high-bioactivation (HB) crosses of Drosophila. An HB
cross is characterized by an increased cytochrome P450-
dependent bioactivation capacity for promutagens when
compared with an ST.
Each ampoule of the DXR commercially known as
Adriblastina
® RD (CAS 23214-92-8) (lot nº G0421), man-
ufactured by Pharmacia & Upjohn S.p.A., Milan, Italy, and
imported and distributed by Pharmacia of Brazil, Ltd., con-
tains chlorohydrate of doxorubicin (10 mg), methylpara-
bene (1 mg) and lactose (50 mg), with Registry Number
1.2389.0046 in the Ministry of Health.
Lapachol (CAS 84-79-7) was provided by Dr. A. B.
Oliveira (Federal University of Minas Gerais, Belo Hori-
zonte, Minas Gerais, Brazil). The molecular structures of
the test drugs are depicted in Figure 1. Solutions of these
compoundswerepreparedwithethanol5%justbeforeuse.
Three mutant strains of Drosophila melanogaster
(ORR, flr
3 and mwh), with the genetic markers of multiple
wing hairs (mwh, 3-0.3) and flare-3 (flr
3, 3-38.8), were
used.
Female virgins flr
3/In(3 LR)TM3, ri pp sep
I(3)89Aa bx
34e and Bd
s were crossed with mwh/mwh
males to produce the ST cross (Graf et al., 1989). The
high metabolic bioactivation cross, with high constitu-
tive levels of cytochrome P450 was the result of crossing
the female virgins ORR/ORR; flr
3/In(3 LR)TM3, ri p
p sep
I(3)89Aa bx
34e and Bd
s with mwh/mwh males (Graf and
van Schaik 1992).
The resultant larvae of both genotypes were simulta-
neously treated with LAP, to facilitate future contact with
the chemical agents to be tested. Larval descendents were
collected over an 8 h period in culture jars containing a
solid agar base (3% of agar in water), with the addition of a
layer of live baker’s yeast (Sachcaromyces cerevisiae) and
sugar. After three days (72 + 8 h), the larvae were washed
out with tap water through a fine-mesh stainless steel
strainer.
Larvae from both crosses were transferred to glass
tubes, 2.5 cm in diameter and 8.0 cm high, each containing
1.5 g of instant mashed potatoes (HIKARI, Lot
nºL3068DD,SãoPaulo,Brazil)and5.0mLofLAP(20,40
and 60 g/mL). The concentrations used in this experiment
were based on studies of the lethal dose of lapachol in
Aedes aegypti larvae (Rodrigues et al., 2005). DXR
(0.125 mg/mL) constituted the positive control, whereas
ethanol 5% was used as the negative. As some compounds
were photosensitive, all the tubes were wrapped in alumi-
num foil. Both control and treated larvae fed on the mashed
potatoes until pupation (48 h).
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Figure 1 - Chemical structures of LAP and DXR.Each cross produce two types of progeny, that is,
marker-heterozygous (MH) (mwh flr
+/mwh
+ flr
3) and bal-
ancer-heterozygous (BH) (mwh flr
+/mwh
+ TM3, Bd
s) flies,
ThedominantBd
smarkerallowsthewingsofthesetwoge-
notypes to be distinguished.
The agents tested (LAP and DXR) were prepared in
ethanol 5% when the larvae were treated. All experiments
were performed at a temperature of (25  2 °C) and at a hu-
midity of 65%. After hatching, the individual adults that
emerged were transferred into a recipient containing 70%
ethanol,andthewingsweremountedonslideswithFaure’s
solution, and analyzed under a compound microscope at
400x magnification (Graf et al., 1984). Frequency and the
size of single and twin spots were recorded.
The statistical analysis of the experiment to verify
possible genotoxic action of LAP was carried out using a
test described by Frei and Würgler (1988), which makes
four different diagnoses: positive, weakly positive, nega-
tive, or inconclusive. The frequency of each type of mutant
cloneperflyofatreatedserieswascomparedpairwise(i.e.,
control vs. LAP) using the conditional binomial test of
Kastenbaum and Bowman (1970). For the final statistical
analysis of all positive outcomes, the nonparametric
Mann-Whitney U-test with significance levels  =  =0 .05
was used to exclude false positives (Frei and Würgler
1995).
Allthecompoundsweretestedintwodifferentexper-
iments.Thedatawerepooledafterverifyingthatthetwoin-
dependent experiments were in agreement with good
reproducibility. Table 1 shows the frequency of mutant
spots observed in the marker-heterozygous and balancer-
heterozygousdescendantsofSTcrossandHBcross.Statis-
tically, significant elevation was not observed (p > 0.05) on
the frequencies of the spots induced by Lapachol (LAP) in
the ST cross, in the three treated doses, when compared to
thenegativecontrolgroup,inallthecategoriesofspots.On
the contrary, there was a positive response in HB des-
cendents,withincreasedfrequencyofsmallsingleandtotal
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Table 1 - Summary of results in the Drosophila SMART assay after treatment with Lapachol (LAP). Larvae from Standard (ST) cross and High
Bioactivation (HB) cross.
Spots per fly (Nº of spots); stat. diagnoses
a
Series Small single spots Large single
spots
Twin Total spots Spots with
mwh clone
c
Mean clone
size class
Frequency of clone for-
mation per 10
5 cells
d
DXR
(mg/mL)
LAP
(g/mL)
Nº of flies (1-2 cells)
b (> 2 cells)
b Observed Control
corrected
ST cross
mwh/flr
3
0 0 50 0.44 (22) 0.08 (04) 0.00 (00) 0.52 (26) 26 1.88 1.07
0.125 0 50 0.84 (42) + 0.52 (26) + 0.52 (26) + 1.88 (94) + 68 2.49 2.79 2.86
0 20 60 0.52 (31) - 0.08 (05) i 0.00 (00) i 0.60 (36) - 36 1.83 1.23 0.16
0 40 60 0.32 (19) - 0.07 (04) i 0.02 (01) i 0.40 (24) - 23 2.04 0.79 -0.28
0 60 60 0.35 (21) - 0.10 (06) i 0.03 (02) i 0.48 (29) - 27 2.11 0.92 -0.14
mwh/TM3
0 0 50 0.04 (02) 0.04 (02) 0.08 (04) 4 2.00 0.16
0.125 0 50 0.10 (05) i 0.06 (03) i 0.16 (08) i 8 2.50 0.33 0.16
HB cross
mwh/flr
3
0 0 50 0.62 (31) 0.04 (02) 0.04 (02) 0.70 (35) 33 1.64 1.35
0.125 0 50 2.04 (102) + 0.22 (11) + 0.32 (16) + 2.58 (129)
+
113 1.64 4.63 3.28
0 20 60 0.93 (56) + 0.10 (06) i 0.02 (01) i 1.05 (63) + 62 1.55 2.12 0.77
0 40 60 1.08 (65) + 0.13 (08) i 0.07 (04) i 1.28 (77) + 73 1.70 2.49 1.14
0 60 60 1.25 (75) + 0.10 (06) i 0.05 (03) i 1.40 (84) + 81 1.54 2.77 1.41
mwh/TM3
0 0 50 0.44 (22) 0.08 (04) 0.52 (26) 26 1.58 1.07
0.125 0 50 0.44 (22) - 0.04 (02) i 0.48 (24) - 24 1.46 0.98 -0.08
0 20 50 0.30 (15) - 0.04 (02) i 0.34 (17) - 17 1.29 0.70 -0.37
0 40 50 0.40 (20) - 0.02 (01) - 0.42 (21) - 21 1.48 0.86 -0.20
0 60 50 0.40 (20) - 0.00 (00) - 0.40 (20) - 20 1.20 0.82 -0.25
aStatisticaldiagnosesaccordingtoFreiandWürgler(1988):+,positive;-,negative;i,inconclusive;m,multiplicationfactor.Kastenbaum-Bowmantests,
onesided.Probabilitylevels==0.05.
bIncludingrareflr
3singlespots.
cConsideringmwhclonesfrommwhsingleandtwinspots.
dFrequencyofclone
formation: clones/flies/48,800 cells (without size correction). DXR, doxorubicin; LAP, lapachol.spots (for 20, 40 and 60 g/mL LAP). DXR produced a
positive response in both ST and HB descendants, thereby
confirming its genotoxicity.
Sousa et al. (2009) showed that a commercial prepa-
ration of the powdered bark and stem of Tabebuia
impetiginosa,althoughtoxic,didnotinducesomaticmuta-
tion and recombination in D. melanogaster from ST and
HB crossbreeding. The absence of genotoxicity, in this
case, could be due to the low concentration of lapachol in
exposedlarvae.However,theseauthorsindicatedthatpow-
dered bark and stem of T. impetiginosa possess a consider-
able potentiating effect on DXR genotoxicity.
The analysis of flies with genotype mwh/TM3 was
carried out for the purpose of calculating the portion of
recombinogenicandmutagenicevents.Itispossibletosep-
arate mutational events from recombinational events, be-
cause the recombinational events are eliminated in flies
with this genotype. A comparison of clone-induction fre-
quencies obtained for DXR in both genotypes indicated
that in ST flies, 12% of mutant clones produced by DXR
were due to mutation and 88% to recombination. Further-
more, the very same analysis showed that in HB flies, 21%
ofspotsinducedbyDXRwereduetomutation,and79%to
recombination. The strong recombinogenic activity of
DXR in somatic cells of D. melanogaster was earlier re-
ported by Lehmann et al. (2003), Costa and Nepomuceno
(2006) and Fragiorge et al. (2007). Our results indicated
that recombinogenicity is the major genotoxic effect of
LAP 20 g/mL (approximately 67% through recombina-
tion), LAP 40 g/mL (approximately 65.5% recombina-
tion) and LAP 60 g/mL (approximately 70% recombina-
tion). There are no published articles on LAP genotoxicity,
and the mutagenicity of this chemical was only studied on
the Ames test (Krishnan and Bastow, 2000). On the other
hand, mitotic recombinogenic activity had neither been
demonstrated nor otherwise quantified. This recombino-
genic activity is demonstrated in this study and also found
in DXR (another quinone), which again shows similarities
in the effects of these drugs.
Numerous quinones play vital roles in the biochemis-
try of living cells, and exert relevant biological activities.
The cytostatic and antimicrobial activities of these qui-
nonesemergebyvirtueoftheirabilitytoactaspotentialin-
hibitors of electron transport, as uncouplers of oxidative
phosphorylation,asDNAintercalatingagents,asbioreduc-
tive alkylating agents, and as producers of reactive oxygen
radicalsbyredoxcyclingunderaerobicconditions(Limaet
al., 2002).
The main LAP toxicity attribute is its capacity to in-
duce oxidative stress (Silva et al., 2003). It has been dem-
onstrated (Kumagai et al., 1997; Kumagai and Shimojo,
2002) that oxidative stress induced by LAP occurs as a re-
sponse to P450 reductase enzyme activities, thereby caus-
ing changes in the DNA. LAP itself has no direct effect on
DNA, although, as can be observed, this is not so when it
interacts with cytochrome P450. Similar results were
obtained in our study that showed an increase in the fre-
quencies of the mutant spots induced by LAP in descen-
dants from HB cross. DNA changes require bioactivation
as processed by cytochrome P450 reductase (CPR), a
diflavin enzyme (Kumagai et al., 1997). Shiah et al. (1999)
were able to demonstrate that beta-lapachone (a semi- syn-
theticderivateofLAP)iscapableofincreasingthelevelsof
H2O2andO2
￿-(oxidativestress)inleukemiacellsofHL-60,
thus inducing apoptosis in the later stages. They also
showed that induced apoptosis can be related or linked to
increased cell H2O2 levels when activated by NAD (P)H/
quinone oxidoreductase.
Quinones are used as a chemotherapy agent since
they act much like LAP. Doxorubicin (DXR) is capable of
producing a series of free radicals in the cell (Keizer et al.,
1990).ThesefreeradicalsproducedbyDXRactdirectlyon
the nucleus, generating unfavorable conditions for cell di-
vision (multiplication). This cytotoxic mechanism is one of
the agents responsible for the anticancer effects of DXR
(Keizer et al., 1990). The DXR requires a metabolic reduc-
tion of the quinone ring for the semiquinone radical to pro-
duce a toxic effect (Ramji et al., 2003).
On the other hand, Krishnan and Bastow (2000) also
indicated that LAP was involved in interference with the
normal function of topoisomerase II (topo II) enzyme.
Esteves-Souzaetal.(2007)showedtheinhibitoryeffectsof
human DNA-topoisomerase II-a by LAP amine deriva-
tives. According to Esteves-Souza et al. (2007) the inhibi-
tory action on DNA-topoisomerase II-a was also evaluated
by a relaxation assay of supercoiled DNA plasmid. A sig-
nificant inhibitory action of the enzyme was observed, and
greater activity on the part of LAP amine derivatives than
the corresponding lawsone derivatives. Cunha et al. (2006)
showed that 2 M of lapachol derivatives significantly hin-
dered topo II-a catalytic activity. This interference in the
DNA-TopoII-drugcomplexmayproduceaDNAtopology
that favors the occurrence of recombinational events (Ba-
guley and Ferguson, 1998). Lehmann et al. (2003) attrib-
uted homologous recombination induced by DXR to a
similar mechanism.
Although homologous recombination is an important
pathway in DNA repair, there is growing evidence that del-
eterious genomic rearrangements may result from homolo-
gousrecombination,whichmeansthathomologousrecom-
bination events may play a causative role in carcinogenesis
(Arossi et al., 2009). The transformation of normal cells
into cancer cells is a multistep process, with mitotic recom-
bination as a mechanism involved in bringing about such
transformation (Nowell, 1976; Barrett, 1993). In heterozy-
gous cells, bearing a mutant and normal alleles for a tumor
suppressor gene, the somatic recombination may turn up to
be a promoter of neoplasms by inducing homozygosis of
the mutant tumor suppressor, allele (Maher et al., 1993;
Sengstag, 1994).
Costa et al. 561It can be said that LAP, a quinone belonging to the
naphthoquinone group, under the experimental conditions
mentioned in this study is genotoxically active through re-
combination, as verified by wing-spot test of Drosophila
melanogaster. This genotoxicity was only observed in de-
scendants of the crossing of high metabolic bioactivation
(HB). These results demonstrate that LAP, in the analyzed
concentration, is an indirect genotoxic agent, thus indicat-
ing the need for metabolic bioactivation by the cytochrome
P450 enzyme.
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